A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF subjects).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
Madera, California 93636, United States
Hollywood, Florida 33021, United States
Peoria, Illinois 61637, United States
Minneapolis, Minnesota 55404, United States
Albuquerque, New Mexico 87131, United States
Cleveland, Ohio 44106, United States
Toledo, Ohio 43606, United States
Milwaukee, Wisconsin 53226, United States
Qubec, Canada
Benite Cedex, France
Erlangen, Germany
Heidelberglaan, Netherlands
Brimingham, United Kingdom